OBJECTIVE: Deep venous thrombosis (DVT) is a major cause of morbidity and mortality after surgery for primary and metastatic brain tumors. METHODS: We conducted a confidential survey of American neurosurgeons interested in tumor surgery to assess DVT risk awareness and thromboprophylaxis patterns. RESULTS: Of the 172 respondents, 108 (63%) underestimated the DVT risk after brain tumor surgery. After operating on patients who had brain or spinal tumors, 81.4 and 78.5% of respondents, respectively, reported using DVT prophylaxis. After performing brain tumor surgery, 76.2% of respondents reported using solely mechanical methods of prophylaxis "always" or "most of the time." CONCLUSION: American neurosurgeons tend to underestimate the risk of DVT associated with brain tumor surgery and to use mechanical thromboprophylaxis despite the availability of effective pharmacologic antithrombotics. A better appreciation of the risk of thrombosis, combined with clinical studies to address safety, may enhance the use of prophylaxis and the perceived safety of antithrombotics in this setting.
OBJECTIVE:Deep venous thrombosis (DVT) is a major cause of morbidity and mortality after surgery for primary and metastatic brain tumors. METHODS: We conducted a confidential survey of American neurosurgeons interested in tumor surgery to assess DVT risk awareness and thromboprophylaxis patterns. RESULTS: Of the 172 respondents, 108 (63%) underestimated the DVT risk after brain tumor surgery. After operating on patients who had brain or spinal tumors, 81.4 and 78.5% of respondents, respectively, reported using DVT prophylaxis. After performing brain tumor surgery, 76.2% of respondents reported using solely mechanical methods of prophylaxis "always" or "most of the time." CONCLUSION: American neurosurgeons tend to underestimate the risk of DVT associated with brain tumor surgery and to use mechanical thromboprophylaxis despite the availability of effective pharmacologic antithrombotics. A better appreciation of the risk of thrombosis, combined with clinical studies to address safety, may enhance the use of prophylaxis and the perceived safety of antithrombotics in this setting.
Authors: Joeky T Senders; Nicole H Goldhaber; David J Cote; Ivo S Muskens; Hassan Y Dawood; Filip Y F L De Vos; William B Gormley; Timothy R Smith; Marike L D Broekman Journal: J Neurooncol Date: 2017-10-16 Impact factor: 4.130
Authors: Natalie B V Riblet; Evelyn M Schlosser; Jennifer A Snide; Lara Ronan; Katherine Thorley; Melissa Davis; Jennifer Hong; Linda P Mason; Tobi J Cooney; Lanelle Jalowiec; Nancy L Kennedy; Sabrina Richie; David Nalepinski; Camilo E Fadul Journal: Neurooncol Pract Date: 2015-10-23
Authors: Christian Valentin Eisenring; Marian Christoph Neidert; Daniel Sabanés Bové; Leonhard Held; Johannes Sarnthein; Niklaus Krayenbühl Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240